Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | IDH1 | O75874 | 8/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | IL6ST | P40189 | 1/20 | 0.39 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.38 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5058895 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL4192293 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL3963007 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL8863773 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL14175205 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL3963002 | 1.00 | NAAA (0.44) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL17747719 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL17747720 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL17747717 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA | |
| SCHEMBL14175204 | 0.88 | NAAA (0.42) | NAAAABCB1FAAHIDH1PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388598-A1 | RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2025-12-25 | — | — | US | disclosed |
| US-20250368661-A1 | RAS INHIBITORS | REVOLUTION MEDICINES INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. | 2025-06-19 | — | — | US | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230374035-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
| EP-4208261-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | Revolution Medicines, Inc. (US) | 2023-07-12 | — | — | EP | disclosed |
| US-7022825-B2 | Polyketides and antibiotics | KOSAN BIOSCIENCES, INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20060063935-A1 | Inhibitors of animal cell motility and growth | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2006-03-23 | — | — | US | disclosed |
| US-20030236290-A1 | Inhibitors of animal cell motility and growth | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-25 | — | — | US | disclosed |
| WO-2003106437-A1 | 2-OXAZOLIDINONES AND THEIR USE AS INHIBITORS OF ANIMAL CELL MOTILITY AND GROWTH | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2003-12-24 | — | — | WO | disclosed |
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | ASHLEY GARY (US) | 2003-05-22 | — | — | US | disclosed |
| US-20030092140-A1 | Novel polyketides and antibiotics | ASHLEY GARY (US) | 2003-05-15 | — | — | US | disclosed |
| US-6492562-B1 | INVENTION ALSO RELATES TO NOVEL INTERMEDIATES AND THE RESULTING MODIFIED POLYKETIDES AND ANTIBIOTICS. | KOSAN BIOSCIENCES, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1144375-A2 | SYNTHESIS OF OLIGOKETIDES | Kosan Biosciences (US) | 2001-10-17 | — | — | EP | disclosed |
| WO-2000044717-A9 | SYNTHESIS OF OLIGOKETIDES | — | 2001-08-23 | — | — | WO | disclosed |
| WO-2000044717-A2 | SYNTHESIS OF OLIGOKETIDES | KOSAN BIOSCIENCES, INC. (US) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368661-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | NAAA 4114/4885ABCB1 1178/4885FAAH 3735/4885 |
| US-20250195521-A1 | USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS | SOS1, PPM1D, PTPN1 | NAAA 3975/4885ABCB1 3339/4885FAAH 4309/4885 |
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | NAAA 4467/4885ABCB1 2116/4885FAAH 3870/4885 |
| US-20060063935-A1 | Inhibitors of animal cell motility and growth | MKI67, MMP2, MMP1 | NAAA 3047/4885ABCB1 269/4885FAAH 2082/4885 |
| US-20030236290-A1 | Inhibitors of animal cell motility and growth | MMP1, MKI67, MMP2 | NAAA 3357/4885ABCB1 204/4885FAAH 1863/4885 |
| US-20230374035-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | NAAA 4114/4885ABCB1 1178/4885FAAH 3735/4885 |
| US-20250388598-A1 | RAS INHIBITORS | KRAS, NRAS, G3BP2 | NAAA 4490/4885ABCB1 210/4885FAAH 2975/4885 |
| US-20030096374-A1 | Preparation of ketide ester; obtain benzoxazolone derivative, incubate with polyketide synthase, recover ketide oligomer | COASY, KARS1, ACOT7 | NAAA 684/4885ABCB1 2767/4885FAAH 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.